Foreign institutional investors (FIIs) have decreased their holdings in Biocon by over 200 basis points to 10.62% at the end of the third quarter from 13.05% in the second quarter ended September 30, 2014. The Foreign investors have sold 48.6 lakh shares representing 2.43% stake of Biocon during the recently concluded quarter.
On the other hand, domestic institutional investors’ (DIIs’) shareholding in the company has increased by 65 basis points to 7.60% from 6.95% in past three months.
Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
